BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36253876)

  • 1. Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient-derived xenografts.
    Rab R; Ehrhardt A; Achyut BR; Joshi D; Gilbert-Ross M; Huang C; Floyd K; Borovjagin AV; Parker WB; Sorscher EJ; Hong JS
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1708. PubMed ID: 36253876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
    Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.
    Hong JS; Waud WR; Levasseur DN; Townes TM; Wen H; McPherson SA; Moore BA; Bebok Z; Allan PW; Secrist JA; Parker WB; Sorscher EJ
    Cancer Res; 2004 Sep; 64(18):6610-5. PubMed ID: 15374975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.
    Hassan AEA; Abou-Elkhair RAI; Parker WB; Allan PW; Secrist JA
    Eur J Med Chem; 2016 Jan; 108():616-622. PubMed ID: 26724729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
    Rosenthal EL; Chung TK; Parker WB; Allan PW; Clemons L; Lowman D; Hong J; Hunt FR; Richman J; Conry RM; Mannion K; Carroll WR; Nabell L; Sorscher EJ
    Ann Oncol; 2015 Jul; 26(7):1481-7. PubMed ID: 25899782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.
    Parker WB; Allan PW; Waud WR; Hong J; Gilbert-Ross M; Achyut BR; Joshi D; Behbahani T; Rab R; Ealick SE; Sorscher EJ
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):573-583. PubMed ID: 31915968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.
    Parker WB; King SA; Allan PW; Bennett LL; Secrist JA; Montgomery JA; Gilbert KS; Waud WR; Wells AH; Gillespie GY; Sorscher EJ
    Hum Gene Ther; 1997 Sep; 8(14):1637-44. PubMed ID: 9322865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
    Voeks D; Martiniello-Wilks R; Madden V; Smith K; Bennetts E; Both GW; Russell PJ
    Gene Ther; 2002 Jun; 9(12):759-68. PubMed ID: 12040457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
    Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N
    Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.
    Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
    Cancer Gene Ther; 2007 Mar; 14(3):279-86. PubMed ID: 17218950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.
    Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR
    Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.
    Parker WB; Allan PW; Waud WR; Hong JS; Sorscher EJ
    Cancer Gene Ther; 2011 Jun; 18(6):390-8. PubMed ID: 21394111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
    Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
    Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.
    Behbahani TE; Rosenthal EL; Parker WB; Sorscher EJ
    Head Neck; 2019 Jun; 41(6):1979-1983. PubMed ID: 30633420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.
    Bennett EM; Anand R; Allan PW; Hassan AE; Hong JS; Levasseur DN; McPherson DT; Parker WB; Secrist JA; Sorscher EJ; Townes TM; Waud WR; Ealick SE
    Chem Biol; 2003 Dec; 10(12):1173-81. PubMed ID: 14700625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
    Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
    BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.
    Xie X; Guo J; Kong Y; Xie GX; Li L; Lv N; Xiao X; Tang J; Wang X; Liu P; Yang M; Xie Z; Wei W; Spencer DM; Xie X
    J Gene Med; 2011 Dec; 13(12):680-91. PubMed ID: 22009763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.
    Hughes BW; Wells AH; Bebok Z; Gadi VK; Garver RI; Parker WB; Sorscher EJ
    Cancer Res; 1995 Aug; 55(15):3339-45. PubMed ID: 7614469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
    Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
    J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
    Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ
    Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.